Nasdaq grants Brainstorm Cell Therapeutics temporary exception until Oct 21 for bid price compliance

BRAINSTORM CELL THERAPEUTICS INC.

Company received delisting notice on May 1 for failing $1 minimum bid price; appealed on May 2.
Nasdaq granted temporary exception until Oct 21, 2024; must comply by then or face delisting.
If not compliant by mid-August 2024, must execute reverse stock split no later than Oct 7, 2024.
No assurance reverse split will achieve compliance; delisting risk persists if deadline missed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.